Quick filters
- Gilead Sciences to Present at the 23rd Annual Piper Jaffray Healthcare Conference on Tuesday, November 29 Business Wire | Monday November 28, 2011 4:30PM
- Gilead Receives European Marketing Authorization for Eviplera®, a New Complete Once-Daily, Single-Tablet Regimen for HIV-1 Infection in Treatment-Naïve Adults Business Wire | Monday November 28, 2011 1:00PM
- The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Pharmasset, Inc. in Connection with the Sale of the Company to Gilead Sciences, Inc. PR Newswire | Monday November 21, 2011 2:54PM
- Gilead Sciences to buy Pharmasset for $11-billion Globe and Mail | Monday November 21, 2011 7:37AM
- Gilead Sciences to Acquire Pharmasset, Inc. for $11 Billion Business Wire | Monday November 21, 2011 7:00AM
- Gilead Sciences Finalizes Agreement with Tibotec Pharmaceuticals to Develop and Commercialize a Single-Tablet Regimen of Prezista® with Emtriva®, GS 7340 and Cobicistat Business Wire | Tuesday November 15, 2011 4:05PM
- Gilead Sciences to Present at the Lazard Capital Markets 8th Annual Healthcare Conference on Tuesday, November 15 Business Wire | Monday November 14, 2011 4:30PM
- Gilead Sciences to Present at the 2011 Credit Suisse Healthcare Conference on Wednesday, November 9 Business Wire | Tuesday November 8, 2011 4:30PM
- Gilead Sciences and Cardiovascular Research Foundation Initiate Phase 3 Clinical Trial with Ranolazine in Patients Who Have Undergone PCI with a History of Prior Chronic Angina Business Wire | Monday November 7, 2011 8:30AM
- Gilead Announces Positive Five-Year Data Showing Effect of Viread® on Liver Fibrosis and Cirrhosis Caused by Chronic Hepatitis B Business Wire | Saturday November 5, 2011 9:00AM
- Gilead Sciences Announces Third Quarter 2011 Financial Results Business Wire | Thursday October 27, 2011 4:05PM
- Gilead Submits New Drug Application to U.S. FDA for Once-Daily, Single-Tablet “Quad” HIV Regimen Business Wire | Thursday October 27, 2011 4:03PM
- Bristol-Myers Squibb and Gilead Sciences Announce Licensing Agreement for Development and Commercialization of New Fixed-Dose Combination Pill for People Living with HIV Business Wire | Wednesday October 26, 2011 8:30AM
- Gilead and GlobeImmune Announce License and Collaboration Agreement to Develop Therapeutic Vaccine Products for Treatment of Chronic Hepatitis B Infection Business Wire | Monday October 24, 2011 4:25PM
- Gilead Sciences to Release Third Quarter 2011 Financial Results on Thursday, October 27, 2011 Business Wire | Thursday October 20, 2011 4:30PM
- Gilead and Boehringer Ingelheim Sign License Agreement for Novel HIV Non-Catalytic Integrase Inhibitors Business Wire | Wednesday October 5, 2011 6:25PM
- European CHMP Adopts Positive Opinion for Eviplera®, a Once-Daily Single-Tablet Regimen for the Treatment of HIV Infection Business Wire | Friday September 23, 2011 7:12AM
- Gilead Sciences to Present at the UBS Global Life Sciences Conference on Tuesday, September 20 Business Wire | Monday September 19, 2011 4:30PM
- Gilead's Second Pivotal Phase 3 Clinical Study of the Investigational Antiretroviral Quad Regimen Meets 48-Week Primary Objective Business Wire | Monday September 19, 2011 4:05PM
- Gilead Amends Study Design for Ongoing Hepatitis C Clinical Trials That Include GS 9190, Pegylated Interferon and Ribavirin, and Another Direct-Acting Antiviral Agent Business Wire | Sunday September 4, 2011 11:00AM
Live Discussion of GILD on StockTwits